We improve people’s lives
by transforming tomorrow’s treatments


Our Research & Development, as well as reformulation of pharmaceuticals based on our patented technologies, helps to improve challenging health issues.

We believe our focus will change people’s lives.

We research and develop inside obstetrics, oncology, as well as pain and addiction.

Devasting conditions dramatically limit and impact peoples’ lives. We focus on creating genuinely innovative medicines by pushing the boundaries of science.



niche products

AFYX is an innovative niche developer of pharmaceuticals aiming at securing better treatments of diseases with unmet medical needs, such as cancer, women’s health and high-scale pain.

Investor relations

We aim at delivering our investors with continuous updates and information on the development of AFYX. Our latest investor presentation is always available here. Annual reports, financial information and other news from AFYX. Get in touch.


AFYX is a specialty pharmaceutical/biopharmaceutical company established in 2024 through a merger of Lionheart ApS, Inphena ApS and AFYX Therapeutics A/S.

Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry: OXiGENE Inc. (OTLC); Genmab A/S (GMAB) and Y-mAbs Therapeutics, Inc.(YMAB).


We are encouraging creativity and new ideas to drive progress and ensuring openness and clarity in communications and actions.


We build trust through responsible actions and honest relationships. We achieve when we collaborate and all work together.


We are going beyond simply being polite. Respect means treating all employees, clients, vendors and stakeholders with dignity and worth.


Agern Alle 24
DK-2970 Hørsholm

Contact Us

+45 7174 7174